Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Patients who received preoperative semaglutide (Ozempic, Wegovy) for 24.4 weeks lost a median of ... controls prior to ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of ...

Improvement seen in resolution of steatohepatitis without worsening of fibrosis and in fibrosis without worsening of steatohepatitis.

The results of a planned interim analysis conducted at week 72 ... 10.5% with semaglutide and −2.0% with placebo (estimated difference, −8.5 percentage points; 95% CI, −9.6 to −7.4 ...